24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways.
2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including a first trial result, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity.
Upcoming Catalysts: Anticipated Trial Results in 2H 2025
1B/2 Trial – Ovarian Clear Cell Carcinoma (OCCC)
Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5–10% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality.
The Phase 1B/2 study of LB-100 plus the checkpoint inhibitor dostarlimab (GSK) is designed leverage LB-100's synergistic enhancement of immune checkpoint blockade.
Status: Enrolled, with interim safety completed
Upcoming Milestone: Preliminary safety and efficacy data expected Q4 2025
Potential Market Impact: Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies
1B/2 Trial – Advanced Soft Tissue Sarcoma (STS)
Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains poor.LIXTE's Phase 1B/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS.
Status: Dose escalation completed.
Upcoming Milestone: Safety report Q4 2025
Potential Market Impact: The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need
1B Trial – Metastatic Microsatellite Stable (MSS) Colon Cancer
MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors.
LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with+ atezolizumab (Roche) (an ICI), seeking to overcome immune resistance in this cold tumor type.
Status: Trial open, first patients recruited
Potential Market Impact: The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases
Platform Potential and Market Opportunity
LIXTE's strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform's potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence.
Strong IP Position: Multiple issued and pending patents covering composition, methods of use, and combinations
Pipeline Expansion: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma.
Partnership Potential: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities
Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.
About LIXTE Biotechnology Holdings, Inc.
LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma.
More information can be found at: www.lixte.com
24/7 MARKET NEWS, INC DisclaimerPlease go to https://247marketnews.com/lixte-biotechnology/ for further LIXT information and 247marketnews.com LIXT disclosure information.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
CONTACT: CONTACT: 24/7 Market News Editor@247marketnews.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Fed's Goolsbee: want more assurance on inflation to cut in Sept or autumn
By Ann Saphir (Reuters) -Chicago Federal Reserve Bank President Austan Goolsbee on Friday left the door open to supporting an interest-rate cut in September should fresh data prove reassuring, but said recent reports showing a rise in services inflation give him some pause amid what he calls the "stagflationary" impulse from tariffs. "I feel like we still need another one at least to figure out if we're still on the golden path," Goolsbee told CNBC. "If we can assure ourselves or get a hint that for this meeting, or the meetings this fall, that we aren't on an inflationary spiral that looks to be persistent, I still think it makes sense given the strength of the economy to move rates more back to where we think they're going to settle." The U.S. central bank has kept its policy rate unchanged all year as it monitors the impact of the Trump administration's higher tariffs, which Fed policymakers expected would drive up inflation and unemployment and slow the economy. So far the data has not validated their worst fears. With the economy slowing, both economists and financial markets expect the Fed to begin cutting rates again next month. Still, there have been some concerning signs on inflation, along with mixed signs about whether still-strong consumer spending will continue. Data on Friday was a case in point U.S. retail sales increased 0.5% last month after an upwardly revised 0.9% in June, the Commerce Department reported,. This allayed some concerns that a drop in monthly job gains to just 35,000 on average over the last three months signaled a potential plunge in economic activity. Factory output was unchanged compared to June, a separate report showed, a touch better than forecast, but heavy truck output, which is seen as a forward proxy for demand for equipment to deliver goods, fell to the lowest since last October. Yet a different report Friday showed import prices increased 0.4% in July amid a strong rise in the cost of consumer goods. This was a potential warning sign for inflation that followed reports earlier this week that showed a jump in services prices helped push up producer prices in July, and kept consumer prices more elevated than otherwise. "That makes me a little uneasy because that's very unlikely to be caused by tariffs, so I'm hoping that was a blip," Goolsbee said of the producer price index and consumer price index reports. "Let's not overreact to one month of import price data for sure. Let's not overreact to one month of CPI or PPI inflation. But it's at least an area of concern," he said.
Yahoo
12 minutes ago
- Yahoo
How to pick the best long-term investment for your future
It's a photo-finish race to become the new, best long-term investment. What will come out on top? On this week's Financial Freestyle, host Ross Mac speaks with Kid Parchariyanon, founder and managing partner of SeaX Ventures. Kid discusses how SeaX is helping companies develop transformative technologies, and makes his prediction for the best long-term investment between crypto, AI, and biotechnology. For a deep dive on how venture capital is shaping the future of technology, check out this week's episode of Financial Freestyle. Listen and subscribe to Financial Freestyle on Apple Podcasts, Spotify, or wherever you find your favorite podcasts. Financial Freestyle with Ross Mac on Yahoo Finance is dedicated to promoting economic prosperity for all. Through expert insights, practical advice, and inspiring success stories, we empower you to build and grow wealth. Join us on this transformative journey toward financial freedom and inclusive economic growth. Related videos Mortgage broker reveals $112,000 home loan mistake: 'Costing you a bomb' ATO $2,548 tax refund cash boost for 2.6 million Aussies Work from home shift for millions of Aussies as 'clear link' with salaries revealed: '$300,000 or more' ATO superannuation warning for 200,000 Aussies ahead of looming deadline: 'On the hook for penalties' Sign in to access your portfolio
Yahoo
12 minutes ago
- Yahoo
Heat get under tax line, trade Haywood Highsmith to Nets for 2nd round pick
Miami traded forward Haywood Highsmith to the Brooklyn Nets on Friday, a move that gets the Heat under the tax line for this coming season and creates roster flexibility. The Heat are also sending a second-round pick in 2032 to Brooklyn, which is sending a conditional second-round pick in next year's draft to Miami. With Highsmith being moved, Miami now has two open roster spots. Highsmith had knee surgery earlier this month to repair a meniscus issue and the Heat timeline for his return was 8-10 weeks, one that suggested he could be ready for the start of the regular season. The 28-year-old Highsmith averaged 6.5 points and 3.4 rebounds in 74 games last season for Miami. He averaged 5.5 points over parts of four seasons with the Heat. Highsmith will make about $5.6 million this coming season. Brooklyn is able to absorb that into its open cap space, allowing the move to be made without the Nets needing to send salary back to Miami. ___ AP NBA:
